Infinity stock dips as it stops development of lung cancer drug – Boston Business Journal (blog)

by lowes1 on September 25, 2013


MedCity News
Infinity stock dips as it stops development of lung cancer drug
Boston Business Journal (blog)
Stock in Infinity Pharmaceuticals Inc. (Nasdaq: INFI) dipped 4 percent Wednesday as the company said a mid-stage trial of a potential lung cancer drug did not do significantly better than a placebo. The Cambridge biotech said it doesn't plan to start
Infinity dumps lung cancer drug after PhII trial fails survival testFierceBiotech
Infinity Pharma's cancer drug fails mid-stage trial goalsReuters
Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride MarketWatch (press release)

all 7 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: